182 related articles for article (PubMed ID: 36917924)
1. Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors.
Xin Z; You L; Na F; Li J; Chen M; Song J; Bai L; Chen J; Zhou J; Ying B
Eur J Cancer; 2023 May; 184():124-136. PubMed ID: 36917924
[TBL] [Abstract][Full Text] [Related]
2. Immunogenetic polymorphisms predict therapeutic efficacy and survival outcomes in tumor patients receiving PD-1/PD-L1 blockade.
Xin Z; You L; Li J; Na F; Chen M; Song J; Bai L; Chen H; Zhai J; Zhou X; Zhou J; Ying B
Int Immunopharmacol; 2023 Aug; 121():110469. PubMed ID: 37311357
[TBL] [Abstract][Full Text] [Related]
3. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
4. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
6. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
Shi Y; Duan J; Guan Q; Xue P; Zheng Y
Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis.
Song SJ; Song YK; Jang M; Shin E; Suh SY; Cho YS; Lee JY; Oh JM
Target Oncol; 2023 Jan; 18(1):147-158. PubMed ID: 36515782
[TBL] [Abstract][Full Text] [Related]
8. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
9. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
[TBL] [Abstract][Full Text] [Related]
10. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
11. Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients.
Horesh A; Pollack R; Nechushtan H; Dresner-Pollak R; Neuman T
Pathol Oncol Res; 2023; 29():1610951. PubMed ID: 37139142
[No Abstract] [Full Text] [Related]
12. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors.
Maillet D; Corbaux P; Stelmes JJ; Dalle S; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Freyer G; Boespflug A; Péron J
Eur J Cancer; 2020 Jun; 132():61-70. PubMed ID: 32334337
[TBL] [Abstract][Full Text] [Related]
13. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
Cortellini A; Friedlaender A; Banna GL; Porzio G; Bersanelli M; Cappuzzo F; Aerts JGJV; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Berardi R; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Inno A; Di Marino P; Mansueto G; Zoratto F; Santoni M; Tudini M; Ghidini M; Filetti M; Catino A; Pizzutilo P; Sala L; Occhipinti MA; Citarella F; Russano M; Torniai M; Cantini L; Follador A; Sforza V; Nigro O; Ferrara MG; D'Argento E; Leonetti A; Pettoruti L; Antonuzzo L; Scodes S; Landi L; Guaitoli G; Baldessari C; Bertolini F; Della Gravara L; Dal Bello MG; Belderbos RA; De Filippis M; Cecchi C; Ricciardi S; Donisi C; De Toma A; Proto C; Addeo A; Cantale O; Ricciuti B; Genova C; Morabito A; Santini D; Ficorella C; Cannita K
Clin Lung Cancer; 2020 Nov; 21(6):498-508.e2. PubMed ID: 32680806
[TBL] [Abstract][Full Text] [Related]
14. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
15. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
[TBL] [Abstract][Full Text] [Related]
16. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
[TBL] [Abstract][Full Text] [Related]
17. Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors.
Refae S; Gal J; Ebran N; Otto J; Borchiellini D; Peyrade F; Chamorey E; Brest P; Milano G; Saada-Bouzid E
Invest New Drugs; 2020 Feb; 38(1):160-171. PubMed ID: 31402427
[TBL] [Abstract][Full Text] [Related]
18. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Zhang M; Rodrigues AJ; Pollom EL; Gibbs IC; Soltys SG; Hancock SL; Neal JW; Padda SK; Ramchandran KJ; Wakelee HA; Chang SD; Lim M; Hayden Gephart M; Li G
J Neurooncol; 2021 Mar; 152(1):125-134. PubMed ID: 33415659
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Russano M; Cortellini A; Giusti R; Russo A; Zoratto F; Rastelli F; Gelibter A; Chiari R; Nigro O; De Tursi M; Bracarda S; Gori S; Grossi F; Bersanelli M; Calvetti L; Di Noia V; Scartozzi M; Di Maio M; Bossi P; Falcone A; Citarella F; Pantano F; Ficorella C; Filetti M; Adamo V; Veltri E; Pergolesi F; Occhipinti MA; Nicolardi L; Tuzi A; Di Marino P; Macrini S; Inno A; Ghidini M; Buti S; Aprile G; Lai E; Audisio M; Intagliata S; Marconcini R; Brocco D; Porzio G; Piras M; Rijavec E; Simionato F; Natoli C; Tiseo M; Vincenzi B; Tonini G; Santini D
Cancer Immunol Immunother; 2022 Apr; 71(4):865-874. PubMed ID: 34462870
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.
Cortellini A; Buti S; Bersanelli M; Giusti R; Perrone F; Di Marino P; Tinari N; De Tursi M; Grassadonia A; Cannita K; Tessitore A; Zoratto F; Veltri E; Malorgio F; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Cappellini GCA; De Galitiis F; Vitale MG; Rastelli F; Pergolesi F; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Iacono D; Migliorino MR; Gelibter A; Occhipinti MA; Martella F; Inno A; Gori S; Bracarda S; Zannori C; Mosillo C; Parisi A; Porzio G; Mallardo D; Fargnoli MC; Tiseo M; Santini D; Ascierto PA; Ficorella C
Oncoimmunology; 2020; 9(1):1710389. PubMed ID: 32002308
[No Abstract] [Full Text] [Related]
[Next] [New Search]
